Related Experiment Video
Updated: Aug 14, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Molecular Pathogenesis of MDS
1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115-6084, USA. thomas_look@dfci.harvard.edu
Insights
Myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD) involve clonal chromosomal deletions that inactivate crucial tumor suppressor genes. Identifying these genes is key to understanding myeloid development and advancing MDS treatments.
Area of Science:
- Hematology
- Cancer Genetics
- Molecular Biology
Background:
- Clonal hematopoietic stem and progenitor cell disorders, including myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD), significantly impact both pediatric and adult patients.
- These diseases are characterized by clonal, nonrandom chromosomal deletions (e.g., 7q-, 5q-) that inactivate tumor suppressor genes essential for normal myeloid cell development.
- Identifying these tumor suppressors is challenging due to large deleted regions and the unclear role of haploinsufficiency versus homozygous inactivation.
Purpose of the Study:
- To investigate the role of inactivated tumor suppressor genes in the pathogenesis of MDS and MPD.
- To understand the molecular mechanisms underlying dysfunctional myelopoiesis caused by chromosomal deletions.
- To identify critical genes lost through deletions that contribute to MDS and MPD.
Main Methods:
- Analysis of chromosomal deletions in MDS and MPD patient samples.
- Review of existing literature on genetic features and identified mutations in myeloid diseases.
- Comparative analysis of large deleted regions to pinpoint candidate tumor suppressor genes.
Main Results:
- Chromosomal deletions, such as 7q- and 5q-, are common in MDS and MPD, suggesting the inactivation of tumor suppressor genes.
- While some mutations in known hematopoietic genes (e.g., RUNX1, PU.1) have been identified, most deletion-associated tumor suppressors remain elusive.
- The precise mechanism of myelopoiesis dysfunction (haploinsufficiency vs. homozygous inactivation) requires further clarification.
Conclusions:
- Understanding the molecular basis of MDS and MPD, particularly the function of lost tumor suppressor genes, is critical for developing targeted therapies.
- Advances in MDS treatment are contingent upon a comprehensive understanding of the underlying genetic alterations and their impact on myeloid development.
- Further research is needed to identify the specific tumor suppressor genes affected by chromosomal deletions in these clonal hematopoietic disorders.
Abstract:
Clonal disorders of hematopoiesis, such as myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD), affect both hematopoietic stem cells and progenitor cells within the erythroid, platelet and granulocytic lineages and can have devastating consequences in children and adults. The genetic features of these diseases often include clonal, nonrandom chromosomal deletions (e.g., 7q-, 5q-, 20q-, 6q-, 11q- and 13q-) that appear to inactivate tumor suppressor genes required for the normal development of myeloid cells (reviewed in Bench and Fenaux). These putative tumor suppressors have proved to be much more difficult to identify than oncogenes activated by chromosomal translocations, the other major class of chromosomal lesions in MDS and MPD. Although MDS and MPD are almost certainly caused by mutations in stem/progenitor cells, the role of inactivated tumor suppressor genes in this process remains poorly understood. In a small portion of myeloid diseases, mutations have been identified in genes encoding factors known to be required for normal hematopoiesis, such as PU.1, RUNX1, CTNNA1 (alpha-catenin) and c/EBPalpha, and implicating these genes as tumor suppressors. Nonetheless, the identities of most deletion-associated tumor suppressors in these diseases remains elusive, despite complete sequencing of the human genome. The deleted regions detected by cytogenetic methods are generally very large, containing many hundreds of genes, thus making it hard to locate the critical affected gene or genes. It is also unclear whether dysfunctional myelopoiesis results from haploinsufficiency, associated with the deletion of one allele, or from homozygous inactivation due to additional point mutations or microdeletions of the retained wild-type allele. In general MDS have proved surprisingly resistant to conventional treatments. Targeted therapeutic advances in MDS will likely depend on a full comprehension of underlying molecular mechanisms, in particular the tumor suppressor genes lost through clonal, nonrandom chromosomal deletions, such as the 7q- and (del)5q.
Related Concept Videos
Abnormal Proliferation
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Parkinson Disease ll: Pathophysiology
Satellite Stem Cells and Muscular Dystrophy
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

